{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"81.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"description":"Determined by the Physician's global assessment of autoinflammatory disease activity, assessment of skin disease and inflammation markers. Data expressed as a percent of participants who had experienced a flare by the end of Part II.","groups":[{"description":"ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.","id":"OG000","title":"ACZ885"},{"description":"Placebo subcutaneous injection every 8 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"32 weeks after study start","title":"Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part)","type":"PRIMARY","unitOfMeasure":"percent of participants"}